Interim Data on GenSpera’s G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics

Published: Nov 09, 2012

SAN ANTONIO--(BUSINESS WIRE)--GenSpera, Inc. (OTCBB:GNSZ) announced that interim data from its ongoing Phase I trial of G-202 in patients with advanced solid tumor cancers were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. The main conclusions of the poster, entitled “A First-in-Human, Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-Based PSMA-Activated Prodrug, in Patients with Advanced Solid Tumors,” are that G-202 appears to be well-tolerated when administered via the recommended dosing regimen and that it should be evaluated in Phase II studies. Although the trial was not designed to demonstrate efficacy, evidence of clinical activity was observed in some patients.

Back to news